Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated Myeloma – Cancer Network
Medical Xpress |
Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated Myeloma
Cancer Network A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I (abstract 740) study presented at the … CAR T, immunotherapy bring new hope for multiple myeloma patients 'Unheard of' responses to bluebird CAR–T therapy seen in myeloma study #ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlight |
